The Mutua Madrileña Foundation has awarded the 21st Health Research Grants, worth €2.3 million, to 23 studies and clinical trials aimed at improving medical treatment to be carried out at various research centres throughout Spain. These include two IDIBAPS studies.
Manel Juan’s project will focus on cancer immunotherapy with the aim of developing a cancer therapy based on T lymphocyte receptors (TCR). “Our project aims to improve precision in the identification of tumour antigens and TCRs that safely and effectively recognize tumour cells,” explains Manel Juan.
Eduard Gratacós’ study will use artificial intelligence to try to prevent pre-eclampsia—a complication of pregnancy that can cause problems for both mother and baby—in a personalized way. “Our aim is to prevent each case and use the best possible treatment taking into account their specific characteristics,” says Eduard Gratacós.
About the Mutua Madrileña Foundation grants
In this 21st call for Health Research Grants, the Mutua Madrileña Foundation has allocated over €70 million to contributing to quality medical research in Spain, which has led to the implementation of more than 1,450 projects.
The complete list of projects that have received grants can be consulted here.
In the last call, the Clínic-IDIBAPS also received two grants.
